



UNITED STATES PATENT AND TRADEMARK OFFICE

APR - 1 2008

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 6,639,055. The application was filed on August 23, 2004, under 35 U.S.C. § 156. Applicant also filed for patent term extension for U.S. Patent No. 6,054,297 for BLA No. 125085/0 (FDA Docket No. 2004E-0402).

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571)272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Jeffrey P. Kushan
Sidley Austin Brown and Wood LLP
1501 K Street NW
Washington DC 20005

RE: AVASTIN® (bevacizumab)
FDA Docket No. 2007E-0184